Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
2.990
+0.180 (6.41%)
At close: Dec 20, 2024, 4:00 PM
3.050
+0.060 (2.01%)
After-hours: Dec 20, 2024, 5:34 PM EST
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 16.14, with a low estimate of 14 and a high estimate of 23. The average target predicts an increase of 439.80% from the current stock price of 2.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +368.23% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +669.23% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +669.23% | Oct 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +368.23% | Oct 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $15 | Buy | Reiterates | $15 | +401.67% | Sep 30, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.63
from -1.37
EPS Next Year
-1.63
from -1.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 39.1M | |||
| Avg | n/a | n/a | 11.1M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.59 | -1.27 | -1.45 | |||
| Avg | -1.63 | -1.63 | -1.82 | |||
| Low | -1.64 | -1.96 | -2.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.